Is Phibro Animal Health Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential.
When compared to peers, Phibro Animal Health Corp. has a P/E of 29.58, which is significantly higher than the negative P/E ratios of its risky counterparts like Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. Additionally, the company has demonstrated strong returns, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, reinforcing the attractiveness of its valuation.